The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, Precision Biosciences Inc (NASDAQ: DTIL) closed at $4.49 down -0.66% from its previous closing price of $4.52. In other words, the price has decreased by -$0.66 from its previous closing price. On the day, 0.63 million shares were traded. DTIL stock price reached its highest trading level at $4.638 during the session, while it also had its lowest trading level at $4.37.
Ratios:
For a deeper understanding of Precision Biosciences Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.45 and its Current Ratio is at 3.45. In the meantime, Its Debt-to-Equity ratio is 1.75 whereas as Long-Term Debt/Eq ratio is at 1.66.
On April 30, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $19. On June 17, 2022, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $7.BMO Capital Markets initiated its Outperform rating on June 17, 2022, with a $7 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 16 ’25 when Germano Geno J bought 3,000 shares for $4.72 per share. The transaction valued at 14,160 led to the insider holds 23,883 shares of the business.
Frankel Stanley bought 2,700 shares of DTIL for $12,690 on Dec 16 ’25. The Director now owns 19,478 shares after completing the transaction at $4.70 per share. On Dec 15 ’25, another insider, Brown Melinda, who serves as the Director of the company, bought 1,381 shares for $4.97 each. As a result, the insider paid 6,864 and bolstered with 23,346 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DTIL now has a Market Capitalization of 108082160 and an Enterprise Value of 43780812. For the stock, the TTM Price-to-Sale (P/S) ratio is 154.40 while its Price-to-Book (P/B) ratio in mrq is 3.26. Its current Enterprise Value per Revenue stands at 62.723 whereas that against EBITDA is -0.498.
Stock Price History:
The Beta on a monthly basis for DTIL is 1.20, which has changed by -0.00222224 over the last 52 weeks, in comparison to a change of 0.14402747 over the same period for the S&P500. Over the past 52 weeks, DTIL has reached a high of $8.82, while it has fallen to a 52-week low of $3.61. The 50-Day Moving Average of the stock is -23.64%, while the 200-Day Moving Average is calculated to be -12.91%.
Shares Statistics:
For the past three months, DTIL has traded an average of 188.43K shares per day and 237960 over the past ten days. A total of 24.07M shares are outstanding, with a floating share count of 19.30M. Insiders hold about 19.70% of the company’s shares, while institutions hold 19.31% stake in the company. Shares short for DTIL as of 1764288000 were 636655 with a Short Ratio of 3.38, compared to 1761868800 on 485968. Therefore, it implies a Short% of Shares Outstanding of 636655 and a Short% of Float of 2.6800001.
Earnings Estimates
Currently, 3.0 analysts are dedicated to thoroughly evaluating and rating the performance of Precision Biosciences Inc (DTIL) in the stock market.The consensus estimate for the next quarter is -$0.82, with high estimates of -$0.82 and low estimates of -$0.82.
Analysts are recommending an EPS of between -$5.82 and -$6.67 for the fiscal current year, implying an average EPS of -$6.16. EPS for the following year is -$3.11, with 3.0 analysts recommending between -$1.0 and -$5.21.
Revenue Estimates
A total of 4 analysts believe the company’s revenue will be $9.07M this quarter.It ranges from a high estimate of $12.3M to a low estimate of $8M. As of. The current estimate, Precision Biosciences Inc’s year-ago sales were $638k
A total of 4 analysts have provided revenue estimates for DTIL’s current fiscal year. The highest revenue estimate was $12.3M, while the lowest revenue estimate was $8.06M, resulting in an average revenue estimate of $9.14M. In the same quarter a year ago, actual revenue was $68.7M
